Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru
- Hospital Nacional Carlos Alberto Seguin Escobedo, Servicio de Medicina Nuclear, Arequipa (Peru)
- Universidad Nacional de San Agustín de Arequipa, Escuela de Física, Arequipa (Peru)
The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.
- OSTI ID:
- 22608530
- Journal Information:
- AIP Conference Proceedings, Vol. 1753, Issue 1; Conference: Latin American symposium on nuclear physics and applications, Medellin (Colombia), 30 Nov - 4 Dec 2015; Other Information: (c) 2016 Author(s); Country of input: International Atomic Energy Agency (IAEA); ISSN 0094-243X
- Country of Publication:
- United States
- Language:
- English
Similar Records
SU-E-T-619: Planning 131I Thyroid Treatments for Patients Requiring Hemodialysis
Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer